key: cord-0867851-76zx35g2 authors: Querrey, Melissa; Kurihara, Chitaru; Manerikar, Adwaiy; Garza‐Castillon, Rafael; Lysne, Jeffrey; Tomic, Rade; Budinger, GR Scott; Kim, Samuel; Lung, Kalvin; Yeldandi, Anjana; Bharat, Ankit title: Lung donation following SARS‐CoV‐2 infection date: 2021-08-09 journal: Am J Transplant DOI: 10.1111/ajt.16777 sha: 1e833b51526b08c87da36e321dd14104090f0e9f doc_id: 867851 cord_uid: 76zx35g2 There have been over 177 million cases of COVID‐19 worldwide, many of whom could be organ donors. Concomitantly, there is an anticipated increase in the need for donor lungs due to expanding indications. Given that the respiratory tract is most commonly affected by COVID‐19, there is an urgent need to develop donor assessment criteria while demonstrating safety and “efficacy” of lung donation following COVID‐19 infection. Accordingly, we report an intentional transplant using lungs from a donor with recent, microbiologically confirmed, COVID‐19 infection into a recipient suffering from COVID‐19 induced ARDS and pulmonary fibrosis. In addition to the standard clinical assays, both donor and recipient lungs were analyzed using RNAscope, which confirmed that tissues were negative for SARS‐CoV‐2. Immunohistochemistry demonstrated colocalized KRT17+ basaloid‐like epithelium and COL1A1+ fibroblasts, a marker suggestive of lung fibrosis in COVID‐19 associated lung disease, in the explanted recipient lungs but absent in the donor lungs. We demonstrate that following a thorough assessment, lung donation following resolved COVID‐19 infection is safe and feasible. Foundation for the National Institutes of Health, Grant/Award Number: HL147290, HL147575 and NIH HL145478 There have been over 177 million cases of COVID-19 worldwide, many of whom could be organ donors. Concomitantly, there is an anticipated increase in the need for donor lungs due to expanding indications. Given that the respiratory tract is most commonly affected by COVID-19, there is an urgent need to develop donor assessment criteria while demonstrating safety and "efficacy" of lung donation following COVID-19 infection. Accordingly, we report an intentional transplant using lungs from a donor with recent, microbiologically confirmed, COVID-19 infection into a recipient suffering from COVID-19 induced ARDS and pulmonary fibrosis. In addition to the standard clinical assays, both donor and recipient lungs were analyzed using RNAscope, which confirmed that tissues were negative for SARS-CoV-2. Immunohistochemistry demonstrated colocalized KRT17+ basaloidlike epithelium and COL1A1+ fibroblasts, a marker suggestive of lung fibrosis in COVID-19 associated lung disease, in the explanted recipient lungs but absent in the donor lungs. We demonstrate that following a thorough assessment, lung donation following resolved COVID-19 infection is safe and feasible. clinical research/practice, donors and donation, lung transplantation/pulmonology, lung transplantation: living donor The COVID-19 pandemic has led to concerns related to lung donation following SARS-CoV-2 infection. Here, we describe an intentional lung transplant from a donor with resolved COVID-19 infection into a recipient suffering from severe COVID-19. A 65-year-old man with severe COVID-19 acute respiratory distress syndrome (ARDS) in May 2020 required mechanical ventilation and extracorporeal membrane oxygenation (ECMO) but was weaned after a protracted medical course and discharged to a long-term care hospital. At 6 months following the original diagnosis, he developed combined hypoxemic and hypercapnic respiratory failure requiring readmission. He was unable to be weaned from the ventilator due to poor lung compliance from progressive pulmonary fibrosis ( Figure 1A -D). The patient was referred for lung transplantation approximately 9 months after illness onset and underwent two negative COVID-19 PCRs from bronchoalveolar fluid (BAL), 24 h as part of the transplant evaluation. He was awake, interactive, and participating in physical therapy at the time of listing, while being supported on the mechanical ventilator, consistent with our recent publications. 1,2 The donor was a woman in her 40s who was a social smoker and who sustained brain death due to a drug overdose. She had developed mild AJT QUERREY Et al. COVID-19 with cough and fevers, confirmed positive by PCR of nasopharyngeal swab 7 weeks prior to the donation. At the time of donation, bronchoscopy revealed petechial airway hemorrhage and airway cultures were positive for Staphylococcus aureus (100 000 colonies/ml). Chest radiograph was clear and computed tomography showed mucous plugging, bibasilar atelectasis, and patchy opacities, concerning for aspiration ( Figure 1E ,F). No evidence of pulmonary fibrosis or interstitial lung disease was noted. The PaO2/FiO2 ranged from 280 to 474. Both nasopharyngeal swab and BAL tested negative for SARS-CoV-2 by PCR. Donor lung pulmonary compliance was normal. On manual palpation, there was no scarring noted on the parietal pleura ( Figure 1G ). Selective venous sampling revealed a PaO2/FiO2 ratio of greater than 300 in all four pulmonary veins. Lungs were procured in a standard manner using Perfadex solution (Xvivo) and transported over ice. The recipient underwent standard consent process then underwent sequential double lung transplantation using clamshell thoracotomy. While donor lungs were normal, explanted native lungs revealed interstitial fibrosis ( While the explanted lungs showed extensive KRT17/COL1A1 colocalization, the donor lungs did not ( Figure 3 ). As Our donor had mild COVID-19 infection seven weeks prior but was subsequently tested negative for SARS-CoV-2 using the nasopharyngeal swab. However, viral shedding has been reported for extended durations. 8, 9 Since the nasopharyngeal swab may not exclude replication-competent virus in the lungs, as evident by recent report, 4 that the transmission risk is negligible. Furthermore, these suggestions might not be applicable to non-pulmonary transplants where the risk of transmission of COVID-19 is much lower. It is known that SARS-CoV-2 causes lung damage. 2,10,11 While lung injury might improve, respiratory impairment and diffusion restriction can persist. [12] [13] [14] [15] In general, the SARS-CoV-2 induced lung injury is associated with pulmonary findings of fibrosis on computed tomography. Accordingly, our donor assessment included computed tomography, determination of lung compliance, and blood gases prior to the organ acceptance (Figure 4) This colocalization signifies aberrant and irreversible epithelial repair after lung damage such as COVID-19 pneumonia. While the explanted donor lungs were replete with KRT17+ cells, the donor lungs were negative ( Figure 2 ). This, combined with histological assessment of the allograft, confirms that carefully selected donor lungs with prior COVID-19 infection can have normal architecture. We have summarized our institutional guidelines (Figure 4 ), based on literature review, UNOS/OPTN guidelines, and our centerspecific practices, which are used to assess lungs from select donors with prior, mild COVID-19 infection. We acknowledge that practices will change as more data becomes available. This work was supported by the National Institutes of Health, NIH HL145478, HL147290, and HL147575 (to AB). The authors are thankful to Ms. Elena Susan for formatting and submission of the manuscript to the journal. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. The data that support the findings of this study are available from the corresponding author upon reasonable request. https://orcid.org/0000-0002-1248-0457 Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries Lung transplantation for patients with severe COVID-19 Chest computed tomography findings in asymptomatic patients with COVID-19 Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing Early success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: a report of 10 cases A call to routinely test lower respiratory tract samples for SARS-CoV-2 in lung donors Successful double-lung transplantation from a donor previously infected with SARS-CoV-2 Virological assessment of hospitalized patients with COVID-2019 SARS-CoV-2: the viral shedding vs infectivity dilemma Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19 The longterm impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status Imaging findings in coronavirus infections: SARS-CoV, MERS-CoV, and SARS-CoV-2 Follow-up chest radiographic findings in patients with MERS-CoV after recovery Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study Lung donation following SARS-CoV-2 infection